Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

NCT07538336 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT07538336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07538336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 2, 2026
Completion date
November 1, 2028
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung transplant